阿替普酶不同剂量治疗急性缺血性脑卒中的疗效比较

目的 比较阿替普酶不同剂量治疗急性缺血性脑卒中的疗效。方法 对我院收治的100例缺血性脑卒中患者进行研究，患者就诊时间为2018年10月—2020年10月，根据患者就诊顺序进行分组，每组各50例。对照组采用阿替普酶0.6 mg/kg静脉溶栓治疗，研究组采用阿替普酶0.9 mg/kg静脉溶栓治疗。比较两组患者治疗前与治疗后美国国立卫生院神经功能缺损（NIHSS）评分、改良Rankin量表（mRS）评分、炎症因子水平、治疗总有效率以及不良反应发生率。结果 两组患者治疗前以及治疗后NIHSS评分、mRS评分比较，差异无统计学意义（P> 0.05）；治疗3个月后复查显示研究组NIHSS评分、mRS评分明显低于对照组，差异有统计学意义（P <0.05）。两组治疗前CRP、IL-6、TNF-α水平比较，差异无统计学意义（P> 0.05）；治疗后研究组CRP、IL-6、TNF-α水平明显低于对照组，差异有统计学意义（P <0.05）。两组治疗总有效率与不良发生发生率比较，差异无统计学意义（P> 0.05）。结论 低剂量与标准剂量阿替普酶治疗缺血性脑卒中的近期疗效与安全性...

Comparison of Therapeutic Effects of Different Doses of Alteplase in the Treatment of Acute Ischemic Stroke

Objective To compare the efficacy of alteplase at different doses in the treatment of acute ischemic stroke.Methods A total of 100 patients with ischemic stroke admitted to our hospital were studied.The time of visit was from October 2018 to October 2020.The patients were grouped according to the order of visit,50 patients in each group.The control group was treated with intravenous thrombolysis with 0.6mg/kg aputease,while the study group was treated with intravenous thrombolysis with 0.9mg/kg aputease.NIHSS score,mRS score,inflammatory factor level,total effective rate of treatment,and incidence of adverse reactions were compared between the two groups before and after treatment.Results There was no significant difference in NIHSS score and mRS score between the two groups before and after treatment(P>0.05).After 3 months of treatment,the reexamination showed that the NIHSS and mRS scores of the study group were significantly lower than those of the control group,and the differences were statistically significant(P<0.05).There was no significant difference in the level of CRP,IL-6 and TNF-αbefore treatment between the two groups(P>0.05).After treatment,the levels of CRP,IL-6 and TNF-αin the study group were significantly lower than those in the control group,and the differences were statistically significant(P<0.05).There was no significant difference in the total effective rate and incidence of adverse events between the two groups(P>0.05).Conclusion The short-term efficacy and safety of low dose and standard dose of aptease in the treatment of ischemic stroke are comparable,but the standard dose is more effective in reducing inflammation and improving the prognosis of patients with ischemic stroke.